FOLH1 and metastatic neoplasm: The increasing, but still limited availability of 18F-labeled PSMA ligands with negligible urinary excretion such as 18F-PSMA-1007 and, more recently 18F-AlF-PSMA-11, provide better accuracy in the visualization of bladder wall lesions along with metastatic disease, where present.